Tag: Farxiga

AZ’s Farxiga granted Priority Review in US for chronic kidney disease

AstraZeneca advances leadership in renal disease at ASN Kidney Week 2020 Reimagined

AZ’s Farxiga-Tracked heart failure following acute myocardial infarction

Farxiga approved in the US for the treatment of heart failure in patients with heart failure with a reduced ejection fraction

FDA approves new treatment for a type of heart failure

AstraZeneca and Saint Luke’s Mid America Heart Institute initiate Phase III DARE-19 trial with Farxiga in COVID-19 patients

Farxiga reduced the incidence of heart failure worsening or cardiovascular death in a sub-analysis from landmark Phase III DAPA-HF trial

FDA approved AstraZeneca’s Farxiga(dapagliflozin) for Priority Review for the patients with heart failure with reduced ejection fraction